Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
van Nieuwkoop, Ceesvan der Starre, Willize E
Stalenhoef, Janneke E
van Aartrijk, Anna M
van der Reijden, Tanny J K
Vollaard, Albert M
Delfos, Nathalie M
van 't Wout, Jan W
Blom, Jeanet W
Spelt, Ida C
Leyten, Eliane M S
Koster, Ted
Ablij, Hans C
van der Beek, Martha T
Knol, Mirjam J
van Dissel, Jaap T
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women.Published in
BMC Med 2017; 15(1):70Publiekssamenvatting
In adults with febrile urinary tract infection (fUTI), data on optimal treatment duration in patients other than non-pregnant women without comorbidities are lacking.PMID
28366170ae974a485f413a2113503eed53cd6c53
10.1186/s12916-017-0835-3
Scopus Count
Collections
Related articles
- Oral fosfomycin versus ciprofloxacin in women with E.coli febrile urinary tract infection, a double-blind placebo-controlled randomized controlled non-inferiority trial (FORECAST).
- Authors: Ten Doesschate T, van Mens SP, van Nieuwkoop C, Geerlings SE, Hoepelman AIM, Bonten MJM
- Issue date: 2018 Dec 5
- Procalcitonin, mid-regional proadrenomedullin and C-reactive protein in predicting treatment outcome in community-acquired febrile urinary tract infection.
- Authors: Stalenhoef JE, van Nieuwkoop C, Wilson DC, van der Starre WE, van der Reijden TJK, Delfos NM, Leyten EMS, Koster T, Ablij HC, van 't Wout JJW, van Dissel JT
- Issue date: 2019 Feb 14
- Treatment duration of febrile urinary tract infection (FUTIRST trial): a randomized placebo-controlled multicenter trial comparing short (7 days) antibiotic treatment with conventional treatment (14 days).
- Authors: van Nieuwkoop C, van't Wout JW, Assendelft WJ, Elzevier HW, Leyten EM, Koster T, Wattel-Louis GH, Delfos NM, Ablij HC, Kuijper EJ, Pander J, Blom JW, Spelt IC, van Dissel JT
- Issue date: 2009 Aug 19
- Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial.
- Authors: Sandberg T, Skoog G, Hermansson AB, Kahlmeter G, Kuylenstierna N, Lannergård A, Otto G, Settergren B, Ekman GS
- Issue date: 2012 Aug 4
- Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
- Authors: Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, Tenke P, Nagata TD
- Issue date: 2018 Dec